New hope for Hard-to-Treat lung cancer: expanded access to targeted pill
NCT ID NCT06761976
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This program offers oral sevabertinib to adults with advanced non-small cell lung cancer that has a specific HER2 gene change and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in good enough health to take oral medication. The goal is to provide access when no other options remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
- Money worries and cancer: can talking about both ease the burden?
- Digital navigator aims to cut financial toxicity for young adults with cancer
- Can a simple checklist boost recovery after cancer surgery?
- Leftover blood samples could unlock new medical discoveries